Abstracts tagged "Randomized Trial"

Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 0555 • ACR Convergence 2025
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Melinda J. Gooderham¹, Edward Lain², Robert Bissonnette³, Yu-Huei Huang⁴, Charles Lynde⁵, Matthias Hoffmann⁶, Joseph F Merola⁷, Eingun J. Song⁸, Jessica H. Rubens⁹, Amy M. DeLozier⁹, Ming-Chun Hsu⁹ and Richard B. Warren¹⁰, ¹SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ²Austin Institute for Clinical Research, Sanova Dermatology, Austin, TX, USA, Austin, TX, ³Innovaderm Research, Montreal, QC, Canada, Montreal, QC, ⁴Chang Gung Memorial Hospital & Chang Gung University, Taoyuan City, Taiwan, Taoyuan City, Taiwan (Republic of China), ⁵University of Toronto, Lynde Institute for Dermatology & Lynderm Research Inc, Markham, ON, Canada, ON, Canada, ⁶Dermatology Practice Dr. M Hoffmann, Witten, Germany, Witten, Germany, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁸Frontier Derm, Mill Creek, WA, USA, WA, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁰Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Icotrokinra (ICO), a first-in-class, targeted oral peptide that binds and inhibits the interleukin (IL)-23R, was evaluated in ICONIC-TOTAL (NCT06095102).Methods: This Phase 3 trial included…
Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 1660 • ACR Convergence 2025
Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial
Johannes Knitza¹, Julia Kraus², Martin Krusche³, Isabell Haase³, Philipp Klemm⁴, Axel Hueber⁵, Pfeil Alexander⁶, Ulrich Drott⁷, Sebastian Kuhn⁸ and Jan Philipp Klein⁹, ¹Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, ²Vila Health, Berlin, Germany, ³Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁵Klinikum Nuernberg, Nuernberg, Germany, ⁶Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁷Deutsches Endokrinologisches Versorgungszentrum, Frankfurt, Germany, ⁸Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁹Department of Psychiatry, Psychosomatics and Psychotherapy, University of Lübeck, Lübeck, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress, however access to psychological support remains limited. The aim of this trial (DRKS identifier:…
Abstract Number: 2663 • ACR Convergence 2025
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
David Beck¹, Mael Heiblig², Sinisa Savic³, Marcela ferrada⁴, Arsène Mekinian⁵, Onima Chowdhury⁶, Danielle Hammond⁷, Lachelle D. Weeks⁸, Carmelo Gurnari⁹, Yohei Kirino¹⁰, Sophie georgin-Lavialle¹¹, Sarah A. Buckley¹², Bryan G. harder¹², Sandra Goble¹² and Matthew Koster¹³, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ²Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴University of Maryland, Bethesda, MD, ⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁶Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, ⁸Dana Farber Cancer Institute, Boston, MA, ⁹Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ¹⁰Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹¹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹²Sobi Inc., Waltham, MA, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Treatment poses…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
isabelle peene¹, Gwenny Verstappen², Joke Deprez³, Frans Kroese², Suzanne Arends², Andrew Kelly⁴, Lana Vandersarren⁵, Edward Bowen⁶, Julie Jacobs⁷, Paul Meyvisch⁸, Dirk Elewaut⁹ and Hendrika Bootsma¹⁰, ¹University Hospital Ghent, Ghent, Belgium, ²University Medical Center Groningen, Groningen, Netherlands, ³Ghent University, Ghent, Belgium, ⁴Argenx, Philadelphia, PA, ⁵Argenx, Boston, MA, ⁶IQVIA, Stevenage, United Kingdom, ⁷argenx, Ravels, Belgium, ⁸argenx, Ghent, Belgium, ⁹VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹⁰UMCG, Groningen, Netherlands
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
Abstract Number: 1662 • ACR Convergence 2025
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Anna-Maria Hoffmann-Vold¹, Shervin Assassi², Vincent Cottin³, Michael Kreuter⁴, Claudia Valenzuela⁵, Marlies S Wijsenbeek⁶, Hui Gu⁷, Ivana Ritter⁸, Susanne Stowasser⁸, Gerrit Weimann⁸ and Toby M Maher⁹, ¹Oslo University Hospital, Oslo, Norway, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, ⁵Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, ⁶Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles
Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
Abstract Number: 2671 • ACR Convergence 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Sebastian Rodriguez-Garcia², Agna Neto³, Despoina Papadopoulou⁴, Ben Van Baelen³, Paul Duncombe³, Leentje De Ceuninck⁵, Bas van der Woning⁶ and Hector Chinoy⁷, ¹University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ²Hospital Universitario de La Princesa, Madrid, Spain, ³argenx, Ghent, Belgium, ⁴argenx, Alimos Attikis, Greece, ⁵argenx, Issy-les-Moulineaux, France, ⁶argenx BV, Boston, MA, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare, systemic, autoimmune, rheumatic disease, with different subtypes, characterized by muscle weakness and extra-muscular involvement. There are no…
Abstract Number: 0260 • ACR Convergence 2025
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Lachelle D. Weeks¹, Danielle Hammond², Sinisa Savic³, Mael Heiblig⁴, Onima Chowdhury⁵, Arsène Mekinian⁶, Carmelo Gurnari⁷, Radhakrishanan Ramchandren⁸, Sophie georgin-Lavialle⁹, Marcela ferrada¹⁰, Sarah A. Buckley¹¹, Bryan G. harder¹¹, Sandra Goble¹¹, David Beck¹² and Matthew Koster¹³, ¹Dana Farber Cancer Institute, Boston, MA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁶Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁷Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁸University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁰University of Maryland, Bethesda, MD, ¹¹Sobi Inc., Waltham, MA, ¹²Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
Abstract Number: 0558 • ACR Convergence 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana¹, Marta Polak¹, Sharan Nischal¹, Elizabeth Chen¹, Deepika Balakrishna², Ching-Heng Chou¹, Christopher Sisk³, Lynn Tomsho¹, Arun Kannan¹, Cynthia DeKlotz¹, Megan Miller⁴, Joseph Cafone³, Paul Newbold¹, Ya-Wen Yang¹, Monica Leung¹, Dawn Waterworth¹, Nina Sabins¹, Anna Perillo⁵, Andreas Pinter⁶ and Robert Bissonnette⁷, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ²Johnson & Johnson, San Diego, CA, USA, San Diego, USA, ³Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ⁵The Rockefeller University, New York, NY, USA, New York, NY, ⁶Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany, ⁷Innovaderm Research, Montreal, QC, Canada, Montreal, QC
Background/Purpose: Icotrokinra (ICO), a first-in-class targeted oral peptide that blocks the interleukin (IL)-23R and inhibits IL-23 pathway signaling, is being evaluated in the phase 3…
Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Robert Keenan¹, Puja Khanna², Zancong Shen³, Sarah Morris³, Pamela Mundell⁴, Wen Wei⁴, Elizabeth Polvent⁵, Vijay Hingorani⁶, Shunqi Yan⁵ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, Raleigh, NC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthrosi therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., San Diego, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].